Issue Date: September 12, 2011
Anacor Extends R&D Deals
Anacor Pharmaceuticals has expanded R&D collaborations for its boron-based anti-infective agents. GlaxoSmithKline now has the option to obtain rights related to the bacterial enzyme target leucyl-tRNA synthetase and to add programs for tuberculosis and malaria. In return, Anacor will receive $5.0 million up front and R&D and milestone payments of up to $11.3 million through 2012. Separately, the U.S. government just granted GSK up to $94 million to support, among other things, the . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society